Market Research Logo

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015

Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2015’, provides an overview of the Systemic Sclerosis (Scleroderma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Systemic Sclerosis (Scleroderma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Systemic Sclerosis (Scleroderma) Overview
Therapeutics Development
Pipeline Products for Systemic Sclerosis (Scleroderma) - Overview
Pipeline Products for Systemic Sclerosis (Scleroderma) - Comparative Analysis
Systemic Sclerosis (Scleroderma) - Therapeutics under Development by Companies
Systemic Sclerosis (Scleroderma) - Therapeutics under Investigation by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Systemic Sclerosis (Scleroderma) - Products under Development by Companies
Systemic Sclerosis (Scleroderma) - Products under Investigation by Universities/Institutes
Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development
Allergan Plc
Angion Biomedica Corp.
arGentis Pharmaceuticals, LLC
Bayer AG
BioLineRx, Ltd.
BiOrion Technologies B.V.
Bristol-Myers Squibb Company
Celgene Corporation
Corbus pharmaceuticals, Inc.
CSL Limited
Daval International Limited
Digna Biotech, S.L.
F. Hoffmann-La Roche Ltd.
Fibrocell Science, Inc.
GlaxoSmithKline Plc
iBio, Inc.
Inventiva SAS
Kadmon Corporation, LLC
MedImmune, LLC
NovaLead Pharma Pvt. Ltd.
Peptinov SAS
Stratatech Corporation
Vida Therapeutics Inc.
VivaCell Biotechnology Espana S.L.
Systemic Sclerosis (Scleroderma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acALY-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aimspro - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANG-3070 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARG-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-1110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BOT-191 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-82 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-220 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
disitertide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
factor XIII (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FCX-013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-2330811 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBIOCFB-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
inebilizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVA-337 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JBT-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KD-025 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NLP-491 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligonucleotide for Scleroderma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PAT-048 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PPV-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
riociguat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NFkB for Immunology and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Crohns Disease, Systemic Sclerosis and Multiple Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
StrataGraft Skin Tissue - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tocilizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VCE-0048 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEDA-1209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VTI-1000 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Systemic Sclerosis (Scleroderma) - Recent Pipeline Updates
Systemic Sclerosis (Scleroderma) - Dormant Projects
Systemic Sclerosis (Scleroderma) - Discontinued Products
Systemic Sclerosis (Scleroderma) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2015: Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab for the Treatment of Systemic Sclerosis
Aug 19, 2015: Corbus Pharmaceuticals' Investigational Drug Resunab Granted Fast Track Status by the U.S. FDA for the Treatment of Systemic Sclerosis
Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
Jun 12, 2015: Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab for the Treatment of Systemic Sclerosis (Scleroderma)
Jun 10, 2015: Roche receives U.S. FDA breakthrough therapy designation for ACTEMRA/RoACTEMRA in systemic sclerosis, and will present new study results at EULAR 2015
Apr 27, 2015: iBio Arranges Production of IBIO-CFB03 for Clinical Development With Caliber Biotherapeutics
Mar 09, 2015: Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab
Feb 02, 2015: Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Jan 07, 2015: Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Dec 10, 2014: iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2015
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals, LLC, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by BioLineRx, Ltd., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies B.V., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Celgene Corporation, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Corbus pharmaceuticals, Inc., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by CSL Limited, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Daval International Limited, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Digna Biotech, S.L., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science, Inc., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by iBio, Inc., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva SAS, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corporation, LLC, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune, LLC, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corporation, H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by Vida Therapeutics Inc., H2 2015
Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana S.L., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Systemic Sclerosis (Scleroderma) Therapeutics - Recent Pipeline Updates, H2 2015
Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2015
Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2015
Number of Products under Development for Systemic Sclerosis (Scleroderma) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report